Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets. by Wang, Lulan et al.
UCLA
UCLA Previously Published Works
Title
Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and 
Ferrets.
Permalink
https://escholarship.org/uc/item/2w18b918
Journal
Cell host & microbe, 21(3)
ISSN
1931-3128
Authors
Wang, Lulan
Liu, Su-Yang
Chen, Hsiang-Wen
et al.
Publication Date
2017-03-01
DOI
10.1016/j.chom.2017.02.007
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Article
Generation of a Live Attenuated Influenza Vaccine
that Elicits Broad Protection in Mice and FerretsGraphical AbstractHighlightsd Attenuated influenza virus mutant W7-791 was identified
based on in vivo growth screening
d A single dose of W7-791 fully cross-protected against
multiple influenza viruses in mice
d W7-791-elicited cross-protective T cell responses were
transferable
d A single dose of W7-791 improved viral clearance in ferretsWang et al., 2017, Cell Host & Microbe 21, 334–343
March 8, 2017 ª 2017 Elsevier Inc.
http://dx.doi.org/10.1016/j.chom.2017.02.007Authors
Lulan Wang, Su-Yang Liu,
Hsiang-Wen Chen, ..., Paul Zhou,
F. Xiao-Feng Qin, Genhong Cheng
Correspondence
fqin1@foxmail.com (F.X.-F.Q.),
gcheng@mednet.ucla.edu (G.C.)
In Brief
Wang et al. use in vivo screening of a
mutant influenza virus library to identify
W7-791, an attenuated mutant strain. A
single administration of W7-791 provided
heterologous protection against lethal
virus challenge in mice and ferrets.
Adoptive transfer of T cells from W7-791-
immunized mice conferred heterologous
protection to naive animals.
Cell Host & Microbe
ArticleGeneration of a Live Attenuated Influenza Vaccine
that Elicits Broad Protection in Mice and Ferrets
Lulan Wang,1,2,3,12 Su-Yang Liu,3,12 Hsiang-Wen Chen,3,4,12 Juan Xu,1,2,12 Maxime Chapon,3 Tao Zhang,1,2 Fan Zhou,5
Yao E. Wang,3 Natalie Quanquin,3 Guiqin Wang,5 Xiaoli Tian,6 Zhanlong He,7 Longding Liu,7 Wenhai Yu,7
David Jesse Sanchez,8 Yuying Liang,9 Taijiao Jiang,1,2 Robert Modlin,3,10 Barry R. Bloom,11 Qihan Li,7 Jane C. Deng,6
Paul Zhou,5 F. Xiao-Feng Qin,1,2,* and Genhong Cheng1,2,3,13,*
1Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing 100005, China
2Suzhou Institute of Systems Medicine, Suzhou 215123, China
3Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
4Department of Microbiology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai,
Chinese Academy of Sciences, Shanghai 200025, China
6Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, Los Angeles, Los Angeles, CA
90095, USA
7Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming 650106, China
8Department of Pharmaceutical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA
9295K Animal Science/Veterinary Medicine, University of Minnesota, 1988 Fitch Avenue, St. Paul, MN 55108, USA
10Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
11Harvard School of Public Health, Boston, MA 02115, USA
12Co-first author
13Lead Contact
*Correspondence: fqin1@foxmail.com (F.X.-F.Q.), gcheng@mednet.ucla.edu (G.C.)
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New influenza vaccines that provide effective and
broad protection are desperately needed. Live atten-
uated viruses are attractive vaccine candidates
because they can elicit both humoral and cellular
immune responses. However, recent formulations
of live attenuated influenza vaccines (LAIVs) have
not been protective. We combined high-coverage
transposon mutagenesis of influenza virus with a
rapid high-throughput screening for attenuation to
generate W7-791, a live attenuated mutant virus
strain. W7-791 produced only a transient asymptom-
atic infection in adult and neonatal mice even at
doses 100-fold higher than the LD50 of the parent
strain. A single administration of W7-791 conferred
full protection to mice against lethal challenge with
H1N1, H3N2, and H5N1 strains, and improved viral
clearance in ferrets. Adoptive transfer of T cells
from W7-791-immunized mice conferred heterolo-
gous protection, indicating a role for T cell-mediated
immunity. These studies present an LAIV develop-
ment strategy to rapidly generate and screen entire
libraries of viral clones.
INTRODUCTION
Influenza A virus is a major public health problem. In a typical
year, influenza infects as many as 500 million people worldwide334 Cell Host & Microbe 21, 334–343, March 8, 2017 ª 2017 Elsevierand leads to more than 500,000 deaths. In the United States,
5%–10% of the population is infected by influenza virus in an
average season, resulting in 220,000 hospitalizations and
36,000 deaths (WHO, 2003). However, significant mutations
in the virus will bypass host immunity to previously exposed
strains, leading to considerably greater mortality. The devas-
tating ‘‘Spanish flu’’ pandemic of 1918 was one such example,
where the virus itself or complications from secondary infec-
tions killed an estimated 40–50million people worldwide. Vacci-
nation has been the most effective way to prevent the spread of
influenza and its complications. Live attenuated influenza
vaccines (LAIVs) are known to be more immunogenic than inac-
tivated vaccines, likely because they stimulate both humoral
and cell-mediated immune responses (Belshe et al., 2007).
Traditionally, attenuated vaccines such as the measles-
mumps-rubella and influenza vaccines weremade via a forward
genetics approach, using random mutagenesis followed by
rounds of selection in non-physiological conditions, a time-
intensive process that produces few vaccine candidates
(Lamb et al., 1981). Moreover, these vaccines need to be refor-
mulated annually due to antigenic drift and poor cross-protec-
tion against emerging pandemic strains (Jang and Seong,
2012; Krammer and Palese, 2015). In addition to difficulties in
producing and formulating the vaccine, recent findings suggest
that the quadrivalent LAIVs used over the last 3 years have not
been protective. The CDC has actually recommended against
using the LAIV during the 2016-2017 season (Grohskopf et al.,
2016). In a proof-of-principle study, we sought to use the
reverse genetics system of influenza virus and a transposon
mutagenesis system as tools toward the rapid, high-throughput
generation and screening of viral clones with attenuated growth
in vivo as candidate LAIVs.Inc.
Figure 1. Generation of LAV W7-791 Using Genome-wide Mutagenesis and In Vivo Profiling
(A) Six- to eight-week-old C57BL/6 mice were infected with the M gene segment mutant population by i.t. injection (n = 8). Lungs were harvested at the indicated
dpi and homogenized for genotyping. Peaks (M1 gene in green; M2 gene in blue) indicate the amount of viral RNA with insertions at that nucleotide position. Lung
homogenates from PBS- or WT WSN-injected mice serve as negative controls. Clusters A*, B*, and C* are highlighted in red, representing the three types of
observed growth profiles.
(legend continued on next page)
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RESULTS
Generation of LAV W7-791 Using Genome-wide
Mutagenesis and In Vivo Profiling
In contrast to the antigenic variability of the influenza hemagglu-
tinin and neuraminidase genes, the matrix (M) gene segment en-
coding viral capsid protein (M1) and the proton-selective channel
protein (M2) has evolved very slowly in all lineages of the virus
and has been evaluated as a target for universal vaccine devel-
opment (De Filette et al., 2005, 2008; Huleatt et al., 2008; Ilyinskii
et al., 2008; Krammer and Palese, 2015; Neirynck et al., 1999;
Schnell and Chou, 2008; Schotsaert et al., 2009; Tompkins
et al., 2007; Wang et al., 2014). We created a mutant library
comprised of >105 random insertions of a 15 nt sequence, 50-
NNNNNTGCGGCCGCA-30, in the M gene of influenza A/WSN/
1933 H1N1 (WSN), using a Mu-transposon mutagenesis method
previously described (Arumugaswami et al., 2008).We then used
the reverse genetics system of influenza to transfect the M gene
mutant library with the seven complementary segments of wild-
type (WT) WSN into HEK293T cells, creating a mutant virus
library (Figures S1A–S1C). A primer based on the unique
sequence contained within the insert was paired with different
downstream primers along the length of the gene, generating a
genotyping product of a specific length that could be used to
extrapolate the position of the insertion. In this way, the mutation
coverage of the entire viral pool could be visualized simulta-
neously. Analysis of this high-throughput genotyping data
following in vitro infection of the mutant virus library (Figure S1D)
shows that the majority of viable mutants (green peaks) are
located in the non-conserved regions of the M1 and M2 proteins
(Figures S1E and S1F).
In order to search for a potential LAIV, wemonitored the in vivo
growth profiles of the entire mutant virus population. Eight mice
were given an intratracheal (i.t.) injection of the M gene mutant
virus library, and cDNA was synthesized from the RNA recov-
ered from lung homogenates collected 2, 4, 6, and 8 days
post-infection (dpi). Through genotyping, we identified the loca-
tion of each insertion in the pool of surviving mutant viruses at
each time point. We observed three distinct growth profiles in
these viruses (Figure 1A), possibly related to the mutations’
effect on the replication, fitness, or host immune-related proper-
ties of the virus. Cluster A* represents an example of the fast-
growing and likely disease-causing population. Cluster B*
represents a slow-growing population, due either to intrinsically
slow growth or suppression due to the host’s immune response.
By contrast, the viruses in cluster C* grew rapidly during the first
6 days, but were cleared between days 6 and 8. The advantages
of this population are that these candidates persist long enough
to trigger strong immune responses, but are too attenuated to
cause significant disease in the host. We isolated 67 single
mutant clones to screen as potential vaccine candidates
(Figures S2A and S2B). We amplified three mutants in cluster(B) MDCK cells were infected at 0.25 MOI of WT WSN and W7-791 to determine
(C) The insertion position of W7-791 was mapped onto the known M2 crystal str
(D and E) Mouse body weight was monitored for 7 days post-inoculation with
weight ± SEM.
(F and G) The viral titers from the W7-791 (F) or WT WSN (G) inoculation were ev
(H) The weight change of BALB/c pup mice (15 days of age) inoculated with the
336 Cell Host & Microbe 21, 334–343, March 8, 2017C* (W7-757, W7-791, and W7-797) in Madin-Darby canine kid-
ney (MDCK) cells and found thatW7-791 grew to a high titer (Fig-
ure 1B) with a slightly lower cell toxicity (Figure S2C), causing
less cell death as measured by LDH viability assay compared
to the WT WSN virus. The mutant clone W7-791 had the
insertion RHCGRI after the 26th amino acid of the M2 gene (Fig-
ure S2D), which is located on the cytoplasmic portion of the pro-
ton channel (Figure 1C) (Schnell and Chou, 2008). To ensure that
W7-791 does not revert back to the WT WSN strain, we
passaged W7-791 in vitro for multiple generations and found
that the insertion remains unchanged in the genome (data not
shown). To examine the in vivo stability of W7-791, we passaged
the virus consecutively to groups of naive mice at 4 dpi (Figures
S2E–S2G). We found that the W7-791 titer decreased after each
passage, suggesting that the insertion mutation strain remained
attenuated. Intranasal immunization of 6- to 8-week-old mice
with different titrations of W7-791 showed no signs of weight
loss even at 107 TCID50 (50% tissue culture infection dose) per
mouse, while significant weight loss was observed in mice in-
fected with 103 TCID50 of WSN (Figures 1D and 1E) or 10
4
TCID50 of the H3 strain (Figure S3A). Similarly, the viral load in
the lungs ofW7-791-infectedmicemeasured at 6 dpi was nearly
100-fold lower than in the WSN-infected group (Figures 1F and
1G) or the H3-infected group (Figure S3B). Lung samples
collected at 4 dpi in both PBS and W7-791 groups showed no
obvious pathology, whereas WT WSN mice, even at a much
lower dose, showed severe tissue damage (Figure S3C). We
further tested the safety of W7-791 in 15-day-old neonatal
BALB/c mice by intranasal injection (106, 107, or 108 TCID50) of
W7-791 or 104 TCID50 of WSN. The weight loss (Figure 1H)
and lung findings (Figure S3D) suggest thatW7-791 also exhibits
significantly less pathology than WT WSN in neonatal mice. To
test the extent of this particular insertion in causing viral attenu-
ation, we inserted the same mutation into the matrix gene of
influenza A/Puerto Rico/8 H1N1 (PR8), another mouse-adapted
but heterologous H1 strain. We found that this mutant showed
the same level of attenuation compared to its parent strain in vivo
(Figure S4A). Taken together, we have established that the
mutant W7-791 influenza strain is sufficiently attenuated to
cause only a temporary infection and is safe at high titers in
both adult and neonatal mice.
A Single Dose of W7-791 Can Elicit Protection against
Lethal Homologous Influenza Virus Challenge
We next sought to determine whether vaccination with a single
dose of W7-791 could protect mice against a lethal influenza
virus challenge (Figure 2A). One month after i.t. inoculation with
W7-791, mice were given a lethal dose of 4 MLD50 (50% mouse
lethal dose) of WT WSN virus (Figures 2B and 2C). While the
mock-vaccinated group all lost weight and died, all W7-791-
vaccinated mice maintained a normal weight and survived.
Interestingly, W7-791-vaccinated mice also survived withoutthe titer of virus at various time points. Data are mean ± SEM.
ucture in green.
106, 107, or 108 TCID50 of W7-791 (D) or WT WSN (E). Data are mean body
aluated on day 4 and day 6.
indicated titer of W7-791, WSN, or PBS. Data are mean body weight ± SEM.
Figure 2. A Single Dose ofW7-791 Can Elicit
Protection against Lethal Homologous
Influenza Virus Challenge
(A) Schematics of strategies used for mouse im-
munization and challenge.
(B and C) Mice were immunized intratracheally
with 105 PFU of W7-791 (n = 5) or PBS (n = 5). One
month after vaccination, mice were challenged
with 4 MLD50 of WSN. Mouse weight (B) and sur-
vival (C) were measured at the indicated days after
lethal challenge. Data are mean body weight ±
SEM.
(D and E) Mice were immunized intratracheally
with 105 PFU of W7-791 (n = 5) or PBS (n = 5). One
month after vaccination, mice were challenged
with 4 MLD50 of PR8. Mouse weight (D) and sur-
vival (E) were measured at the indicated days after
lethal challenge. Data are mean body weight ±
SEM. ***p < 0.001.showing signs of illness or weight loss after challenge with 4
MLD50 of PR8 virus (Figures 2D and 2E).
A Single Dose of W7-791 Can Elicit Robust Cross-
Protection against Lethal Heterologous Influenza Virus
Challenge
We further explored whether W7-791 could cross-protect
against heterologous highly pathogenic avian influenza (HPAI)
A/Cambodia/P0322095/05 H5N1 (Cam/H5) (Figures 3A and
3B). Groups of BALB/c mice were inoculated intranasally (i.n.)
with 106 plaque-forming units (PFU) of W7-791 and challenged
3 weeks later with 2 MLD50 of Cam/H5. All of the unvaccinated
mice died, but the W7-791-vaccinated mice resisted the chal-
lenge without exhibiting significant weight loss. We extended
our study to another phylogenetic influenza group, A/Victoria/
3/75 H3N2 (Vic/H3) (Figures 3C and 3D). Mice were vaccinated
with 105 PFU of W7-791, and then lethally challenged with 2
MLD50 after 4 weeks. Interestingly, W7-791-vaccinated mice
only lost about 10% of their initial weight at 3–5 dpi with Vic/
H3 before fully recovering, whereas the mock-vaccinated group
succumbed to the H3N2 infection. Furthermore, we challenged
W7-791-immunized mice against an escalated lethal dose of 5
MLD50 of WSN or HK68/H3 (Figure S4B). As before, all of theCell Host &mice that were vaccinated with W7-791
survived the challenge, whereas PBS-
immunized groups succumbed. Lastly,
we tested whether W7-791 could cross-
protect neonatal mice against lethal ho-
mologous and heterologous infections
(Figures 3E and 3F). Fifteen-day-old
BALB/c mice were immunized i.n. with
106 TCID50 of W7-791 or PBS and then
challenged with a lethal dose (105 or 106
TCID50/mice) of WSN, or a lethal dose
(106 or 107 TCID50/mice) of A/Hong
Kong/68 H3N1 (HK68/H3). Again, all
vaccinated mice cleared the virus and
survived the infection. Lastly, we
compared ourW7-791 strain with a quad-rivalent LAIV used over the 2015-2016 season, FluMist. That
LAIV contains attenuated viruses carrying antigens of two influ-
enza B viruses, an H3N2 virus (Switzerland/9715293/2013),
and an H1N1 strain (California/7/2009 pandemic virus). In vivo
immunization and challenge with the same TCID50 showed that
W7-791 confers greater protection to mice against HK68/H3
(Figure S4C). All together, these results illustrate the capacity
of our minimally modified mutant influenza strain to generate
heterosubtypic protection against lethal virus challenge with a
single immunization.
W7-791 Activates Both Humoral and Cell-Mediated
Immune Responses
Live attenuated vaccines are thought to confer broad cross-pro-
tection against heterologous strains through activation of both
humoral and cell-mediated immune responses. To determine
the mechanisms responsible for the protective effects of
W7-791, we immunized mice i.n. with W7-791, then challenged
with WSN or PR8 viruses. We found that W7-791-vaccinated
mice had significantly improved viral clearance against both
viruses (Figure 4A). Surprisingly, W7-791-vaccinated mouse
serum only showed hemagglutination inhibition (HAI) against
WSN and not against heterologous strains PR8, HK68/H3,Microbe 21, 334–343, March 8, 2017 337
Figure 3. A Single Dose of W7-791 Can Elicit Robust Cross-Protection against Lethal Heterologous Influenza Virus Challenge
(A and B) Mice were immunized i.n. with 106 PFU of W7-791 (n = 6) or PBS (n = 5). Three weeks after vaccination, mice were challenged with 2 MLD50 of Cam/H5.
Mouse weight (A) and survival (B) were measured at the indicated days after lethal challenge. Data are mean body weight ± SEM.
(C and D) Mice were immunized i.n. with 105 PFU of W7-791 (n = 9) or PBS (n = 6). One month after vaccination, mice were challenged with 2 MLD50 of Vic/H3.
Mouse weight (C) and survival (D) were measured at the indicated days after lethal challenge. Data are mean body weight ± SEM.
(E and F) Weight change of neonatal mice lethally challenged with WSN (105 or 106 TCID50) (E) or HK68/H3 (10
6 or 107 TCID50) (F) 3 weeks after challenge.
***p < 0.001.A/Wisconsin/2005 H3N2 (Wis/H3), or Cam/H5 pseudotype virus
(Figures 4B and 4C). We further tested the serum using a micro-
neutralization assay against WSN, PR8, and HK68/H3. Mice
vaccinated with W7-791 showed a high neutralization titer
against WSN and a lower level against PR8 and HK68/H3 (Fig-
ure 4D). These findings led us to believe that antibodies may
not be the only source of protection mediated by W7-791.
To differentiate the cross-protective effect of cell-mediated
and humoral responses, we immunized mice i.n. with 106 PFU
of W7-791 or PBS, and collected serum and total T cells from
spleens and lymph nodes 1 month later. We transferred these338 Cell Host & Microbe 21, 334–343, March 8, 2017separately to naive mice and challenged them i.n. with a lethal
dose of WSN or HK68/H3. The directly vaccinated (not trans-
ferred) group was used as a positive control and showed
100% protection. Adoptive transfer of serum from W7-791-
immunized mice gave full protection against WSN, but not
against HK68/H3 (Figure 4E). However, adoptive transfer of
T cells fromW7-791-immunizedmice was able to partially or fully
protect naive mice from HK68/H3 or WSN, respectively (Fig-
ure 4F). This demonstrates that W7-791 vaccination can
generate a T cell-mediated immune response with a heterosub-
typic protective ability. Furthermore, we evaluated CD8 T cell
Figure 4. W7-791 Activates Both Humoral and Cell-Mediated Immune Responses
(A) Viral titers in lung homogenates of vaccinated and unvaccinatedmice, challengedwith lethal WSN or PR8, were quantified by plaque assay at the time of death
or euthanasia.
(B) HAI assay of vaccinated and unvaccinated mouse serum against WSN, PR8, HK68/H3, and A/Wisconsin/05 H3N2. Mean ± SEM.
(C) The level of antibody in vaccinated and unvaccinated mouse serum was measured using Cam/H5 pseudovirus neutralization. Measurements are in relative
light units (RLU). Mean ± SEM.
(D) Microneutralization assay of W7-791 vaccinated or unvaccinated mouse serum against WSN, PR8, and HK68/H3.
(E and F) Survival of mice receiving serum fromW7-791- (n = 14) or PBS-vaccinatedmice (n = 10). Mice were challenged 24 hr later with a lethal dose ofWSN (E) or
HK68/H3 (F).
(G andH) Survival curve of mice receiving T cells fromW7-791- (n = 20) or PBS-immunizedmice (n = 19), subsequently challenged with a lethal dose ofWSN (G) or
HK68/H3 (H). W7-791-vaccinated, but not transferred, mice were used as a control (n = 10).epitopes in the W7-791-vaccinated mice (data not shown). We
found that a large proportion of lung CD8+ T cells in W7-791-
immunized mice were specific to H-2Db-ASNENMETM (NP)
7 days after an H3N1 challenge. These data, combined with
our adoptive T cell transfer experiment (shown in Figures 3F
and 3H), has led us to believe that W7-791 immunization elicits
cross-protective CD8+ T cell responses in our mouse model.
ASingleDose ofW7-791Elicits HeterologousProtection
in the Ferret Model
To further explore the efficacy of W7-791 as an LAIV strain, we
selected the ferret model, which resembles the pathophysiology
of human influenza infectionmore closely than themouse (Maherand DeStefano, 2004; Matsuoka et al., 2009). To evaluate the
clinical response, we inoculated ferrets with 106, 107, and 108
TCID50 of W7-791. We observed no significant changes in tem-
perature (Figure 5A) or clinical symptoms (Figure 5B) after inoc-
ulation with 108 TCID50 of W7-791. W7-791-vaccinated ferrets
showed a significant increase in serum antibody titer (Figure 5C),
but HAI assay confirmed that these antibodies bind to only the
HA from WSN, and not HK68/H3 (Figures 5D) or H5N1 (Fig-
ure S5A). To examine protection against heterologous viruses,
we challenged the ferrets 4 weeks post-immunization with either
106 TCID50 of WSN, 10
6 TCID50 of HK68/H3, or PBS. Ferrets that
had been immunized with 103 and 104.7 TCID50 of W7-791
showed significant reduction in shedding of the challenge virusCell Host & Microbe 21, 334–343, March 8, 2017 339
Figure 5. A Single Dose of W7-791 Elicits Heterologous Protection in the Ferret Model
(A) Temperature curve of ferrets inoculated i.n. with 106, 107, or 108 TCID50 of W7-791 or PBS.
(B) Clinical scores of the ferrets 2 and 3 days post-inoculation with indicated doses of W7-791 or 106 TCID50 of WSN. Clinical signs were evaluated as previously
described (Reuman et al., 1989).
(C) HAI assay showing the increase of anti-W7-791 HA antibody titer from W7-791 inoculated ferrets after vaccination.
(D) HAI assay showing the titer of anti-H1HA or H3HA antibody 21 days post-inoculation.
(E–H) The viral titers (E and F) and the clinical scores (G and H) of the immunized and non-immunized ferrets challenged with 106 TCID50 ofWSN or HK68/H3. Data
are mean body weight ± SEM.within 2 dpi, compared to the unvaccinated group (control WSN
or HK68/H3, respectively) (Figures 5E, 5F, and S5B). The vacci-
nated ferrets displayed an undetectable WSN or HK68/H3 viral
load at 2 or 4 dpi, respectively. The vaccinated ferrets also
showed improved clinical symptoms compared to non-vacci-
nated ferrets (Figures 5G and 5H). These data suggest that a
single dose of W7-791 is safe in ferrets and can also elicit heter-
ologous subtypic protection.
DISCUSSION
We have taken the approach of combining genome-wide muta-
genesis and in vivo growth profile screening for the rapid and
high-throughput development of LAIVs. As proof of principle,
we used this method to uncover a promising LAIV, W7-791,
that is over 100-foldmore attenuated than the parent H1N1 virus,
and is even tolerated in neonatal mice with no observable lung
pathology. This strain could also confer complete cross-protec-
tion against heterologous H3 and H5 subtype influenza strains in
mice. We further demonstrated that the insertion could be
broadly applicable to attenuate other clades of influenza virus.
The knockout or modified influenza M2 has been previously
described as a potential LAIV candidate (Hatta et al., 2011; Wa-
tanabe et al., 2009). This present study explored the untapped
potential of the M protein in generating LAIVs. The quadrivalent
LAIV (FluMist) that was administered in the United States over
the previous three seasons was shown to be ineffective
compared to the inactivated vaccine. Our own comparison be-
tween the 2015-2016 FluMist formulation and W7-791 showed340 Cell Host & Microbe 21, 334–343, March 8, 2017that our mutant H1 strain could confer greater protection in
mice against challenge with an H3 virus than FluMist, which itself
contains an H3 strain component. One possible explanation is
that the primary method of protection in this case was not via
H3-specific epitopes that were otherwise present in the quadri-
valent LAIV, but rather through conserved epitopes still present
in our H1 mutant strain. It is also plausible that W7-791, which
is derived from a mouse-adapted strain, stimulated the immune
system more efficiently through active replication in mice, and
whether it can outperform FluMist in primates remains to be
investigated. Although the reason for the failure of the FluMist
over the last three seasons is under investigation, it was
observed that this failure came at a time when the formulation
was changed to having four viral components. While the inactive
quadrivalent vaccine formulation is still effective, it is possible
that including too many live influenza strains in the vaccine
causes growth competition and reduced infectivity. Therefore,
our strain may simply have been more effective because it was
a single-component vaccine. The failure of FluMist is unfortu-
nate, as live attenuated vaccines induce cell-mediated re-
sponses that are thought to target the more conserved parts of
the virus, giving them the greatest potential for inducing broad
protection against a multitude of strains. This would not only
bypass the need to adjust our vaccines each year to account
for antigenic drift variants, but could also protect us from highly
pathogenic avian strains and novel reassortment viruses that
could become the next influenza pandemic. W7-791 has shown
great promise in its ability to confer protection against lethal het-
erologous influenza H1, H3, and H5 strains in mice (including
neonates) and ferrets. We demonstrated that even a single dose
of W7-791 in mice could induce protection, without the need for
prime-boost strategies or adjuvants. However, we acknowledge
that the current extent of our LAIV characterization is limited.
Future studies could include transferring the insertion to amaster
donor strain used for LAIVs, and expanding the range of the chal-
lenge doses to further evaluate the potential of this candidate
vaccine. It also remains to be seen whether W7-791 will be
successful in animals that have been previously exposed to
influenza virus. In short, the development of a better influenza
vaccine will require much more investigation, and the present
work is only an initial step.
Our study also advances our understanding of the roles of
antibody and T cell responses in influenza infection. Further-
more, we hypothesize that our strategy of screening for a growth
phenotype that permits limited replication in the host and can
elicit both cell-mediated and humoral immune responses
without causing illness may be applicable to finding attenuated
vaccines for other viruses. It would also be interesting to
compare how the innate and adaptive immune systems commu-
nicate in response to influenza infection, an LAIV, or an inacti-
vated vaccine.
This work presents an LAIV development strategy that can
rapidly generate and screen entire libraries of viral clones for
attenuation. We associated a particular viral growth profile in
mice with the ability to elicit both cell-mediated and humoral im-
mune responses without causing significant disease. From a
cluster of viruses showing this ideal level of attenuation, we iden-
tified a promising LAIV candidate. This approach could poten-
tially be implemented to discover attenuated mutants for other
RNA and DNA viruses. It would require no working knowledge
of specific genes or their functions in the virus, but could be
used to establish a comprehensive profiling of the entire genome
in vitro and in vivo. This systemwould also be ideal for expediting
the design of live attenuated vaccines against less understood or
emergent viruses.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T cells were cultured in DMEM supplemented with 5% heat-inacti-
vated fetal bovine serum (FBS). MDCK cells were maintained in DMEM
containing 5% FBS, penicillin/streptomycin (100 U/mL and 50 mg/mL, respec-
tively), and 1 mM sodium pyruvate at 37C with 5% CO2.
Generation of M Gene Segment Mutant Plasmid Library and
Functional Profiling
To create themutant plasmid library of theM gene segment of influenza A virus
A/WSN/1933, a 15-nt sequence (50-NNNNNTGCGGCCGCA-30; N = dupli-
cated 5 nucleotides from target DNA) was randomly inserted by Mu-trans-
poson-mediated mutagenesis (MGS kit, Finnzymes) according to the
manufacturer’s instructions. The M gene mixed mutant pool was transformed
into E. coli DH10B by electroporation at 2.0 kV, 200 U, 25 mF (ElectroMax
DH10B, Invitrogen). The mutant M gene plasmid and seven remaining WT
plasmids were transfected concomitantly into HEK293T cells for virus gener-
ation. Three days after transfection, the supernatant was collected and trans-
ferred to MDCK cells for propagation. Virus was collected after 48 hr, then
either stored or used for further propagation for up to four passages. RNA
was isolated with the TRIzol reagent (Invitrogen) after each generation.
RT-PCRwas carried out with the iScript cDNASynthesis kit (Bio-Rad) to create
cDNA. Three gene-specific forward primers approximately 400 bp apart in the
M-gene segment (50-AGCAAAAGCAGGTAGATATT-30, 50-GGGGCCAAAGAAATAGCACT-30, and 50-TCCTAGCTCCAGTGCTGGTC-30) and a Vic-
labeled insertion-specific mini-primer (50-TGCGGCCGCA-30) were used to
amplify fragments containing the 15 nt insert using KOD Hot-Start polymerase
(Novagen). The PCR conditions were set to 95C for 10 min (1 cycle); 95C for
45 s, 52C for 30 s, and 72C for 90 s (30 cycles); and 72C for 10 min (1 cycle).
The fluorescent-labeled PCR products were analyzed in duplicate with a Liz-
500 size standard (Applied Biosystems) using a 96-capillary genotyper
(3730xl DNA Analyzer, Applied Biosystems) at the UCLA GenoSeq Core facil-
ity. Sequencing data were analyzed for clarity using ABI software, with the
following criteria: (1) all data passed the standard default detection level; (2)
the first 70 bp were removed due to non-specific background noise; (3) all
data were aligned to the nearest base pair in the influenza A WSN matrix
gene; and (4) all genotyping experimental data were normalized with WT
WSN-infected cells, non-transfected cells, and a different gene library as con-
trols. This eliminated non-specific data from the PCR, primers, and the DNA
Analyzer. For infection in vivo, the mutant virus pool was titered, concentrated
by ultra-centrifugation and re-titered, and used for mouse injection. Two dpi,
the lungs were harvested, homogenized, and resuspended in TRIzol for RNA
isolation, followed by the same procedures as described above. PBS or
WSN-infected mice served as controls.
Virus Strains
We used the influenza A/WSN/1933 reverse genetics system to generate sea-
sonal A/H1N1 virus (Hoffmann et al., 2000). This strain is a mouse-adapted
influenza virus and has been used as the parental strain to generate potential
LAIVs using transposonmutagenesis. The eight plasmids containing the cDNA
of A/WSN/33 (gift from Dr. Yuying Liang at Emory University) were transfected
into HEK293T cells using TransIT LT-1 (Panvera) by the manufacturer’s proto-
col. The virus was serially passaged three times in MDCK cells to a final titer of
107.4 PFU/mL. Influenza virus A/Puerto Rico/8/1934 (seasonal A/H1N1 virus)
was a gift from Dr. Yuying Liang. The virus was serially passaged three times
in MDCK cells to a titer of 107.5 PFU/mL. The MLD50 of both strains was deter-
mined in C57BL/6 mice.
Influenza virus A/Victoria/3/75 (seasonal A/H3N2 virus), A/Wisconsin/65/05
(seasonal A/H3N2 virus), and A/Hongkong/68 (seasonal A/H3N1 virus) were
gifts from Dr. Ioanna Skountzou at Emory University. These viruses were
amplified using MDCK cells for two to three passages to a final titer of 105.5
PFU/mL, 105.4 PFU/mL, and 107 PFU/mL, respectively. The MLD50 was deter-
mined in C57BL/6 and BALB/c mice.
Influenza virus A/Cambodia/P0322095/05 (highly pathogenic avian influ-
enza H5N1 virus) was originally isolated from human patients at the Pasteur
Institute in Cambodia (Buchy et al., 2007). Virus was propagated inMDCK cells
and virus-containing supernatants were pooled, clarified by centrifugation,
and stored at 80C. The TCID50 and the MLD50 of the viruses were deter-
mined in MDCK cells and in BALB/c mice, respectively, and were calculated
as described previously (Ding et al., 2011).
Virus Titrations
The concentration of infectious viruses was determined by plaque assay and
end-point titrations. Plaque assays were performed in MDCK cells and calcu-
lated as PFU/mL of supernatant. The viral samples were serially diluted in
dilution buffer (PBS with 10% BSA, CaCl2, 1% DEAE-dextran, and MgCl2).
Diluents were added to a monolayer of MDCK cells in 6-well plates for 1 hr at
37C, and then covered with growth medium containing 1% low-melting
agarose and TPCK-treated trypsin (0.7 mg/mL). Infected cells were stained after
48 hr (1% crystal violet, 20% ethanol, in PBS) to visualize the plaques. Virus
titrations were performed by end-point titration in MDCK cells. MDCK cells
were inoculated with 10-fold serial dilutions of the virus, then washed with
PBS once 1 hr after inoculation, and cultured in DMEM for 48 hr to visualize
cell viability. The viral titer was determined by luminescence assay or by plaque
assay. To measure the growth of individual mutants in vitro (Figure S2B), an
influenza virus-responsive Gaussia luciferase (gLuc) reporter system was
used. Briefly, the gLuc coding region was inserted in the reverse-sense orienta-
tion between a human RNA polymerase I promoter and a murine RNA
polymerase I terminator. The gLuc coding sequence was flanked by the UTRs
from the PA segment of influenza virus A/WSN/33 strain so that gLuc expression
is dependent on influenza virus infection. The gLuc reporter was transfected into
HEK293Ts for 24 hr before the supernatants containing mutant or WT influenzaCell Host & Microbe 21, 334–343, March 8, 2017 341
viruseswere added.Upon active infection, gLuc is released into the supernatant
and can be quantified with Renilla luciferase substrate (Promega).
Animals
Adult Mice
Female C57BL/6 mice, 6–8 weeks old, were purchased from the Jackson Lab-
oratory. All animals were housed in pathogen-free conditions within the UCLA
animal facilities.
Neonatal Mice
Fifteen-day-old BALB/c mice (Vital River Beijing) weighing 6–9 g were inocu-
lated i.n. with PBS, 104 TCID50 of WSN virus, or dilutions of W7-791. For the
dose-dependent experiment, mice were inoculated i.n. with 106, 107, and
108 TCID50 of W7-791. Sixteen days post-treatment, mice were challenged
i.n. with a lethal dose (105 or 106 TCID50/mouse) of WSN or (10
6 or 107
TCID50/mouse) A/Hong Kong/68 H3N1 (HK68/H3) in a 30 mL volume.
Randomly selected mice from each group were sacrificed for pathological ex-
aminations of the lung at 4 and 6 dpi. Then the lungs were homogenized to
measure viral titer using end-point-dilution assays.
Ferrets
Healthy young adult outbred female ferrets (Mustela putorius furo; between 4
and 5 months of age) were purchased from a commercial breeder (Wuxi) and
confirmed to be seronegative by HAI assay to A/WSN/1933 (H1N1), A/Victoria/
3/75 (H3N2), HK68 (H3N1), and W7-791(H1N1). A minimum of three indepen-
dently housed ferrets were inoculated i.n. with 0.5 mL (0.25 mL per nostril) of
106, 107, or 108 TCID50 of W7-791 or PBS. Anesthesia was performed on the
quadriceps muscles of the left hind leg with a total volume of 0.02 mL Lumian-
ning (HuaMu Animal Care). Serum samples were collected at days 0, 7, 14, 21,
and 28 post-immunization for HAI studies. Nasal washes were collected
0–7 days after immunization. Four weeks after immunization, the ferrets
were challenged i.n. with 106 TCID50 of WSN (H1N1) or HK68 (H3N1). Weights
and temperatures were monitored daily for 7 days after inoculation. Nasal
washes were collected 0–7 days after the challenge. Clinical signs were eval-
uated 3 days prior to vaccination, then 9, 11, 13, and 15 dpi, and 2 days prior to
challenge and 1–7 dpi. The clinical signs were scored as previously described
(Reuman et al., 1989). All animal studies were performed according to the
guidelines of the UCLA Animal Research Committee.
Mouse Immunization and Challenge
Female C57BL/6 and BALB/c mice were randomly divided into groups of five
or six mice. Groups were inoculated i.n. or intratracheally with either PBS or
W7-791 in a volume of 50 mL. Intratracheal injection was performed by anes-
thetizing mice intraperitoneally with a ketamine/xylazine mixture, then surgi-
cally exposing the trachea for direct injection of 30 mL of solution with a sterile
27G needle (Shahangian et al., 2009). Four weeks after immunization, all mice
were challenged i.n. or intratracheally with an influenza strain in a 50 mL vol-
ume: A/WSN/1933 (H1N1) at 4 MLD50, A/Puerto Rico/8/1934 (H1N1) at 4
MLD50, A/Cambodia/P0322095/05 (HPAI-H5N1) at 2 MLD50, or A/Victoria/
3/75 (H3N2) at 2 MLD50. Mice were monitored and recorded daily for signs
of illness, such as lethargy, ruffled hair, and weight loss. When mice lost
30% or more of their original weight, they were euthanized and counted as
dead. For the adoptive transfer experiment, female C57BL/6 mice were
randomly divided into two sets of vaccinated or unvaccinated groups. Unvac-
cinated mice were sham immunized, whereas the vaccinated group received
a single dose of W7-791 at 106 PFU/mouse. One set from each group was
used to harvest cells for the transfer experiment 4 weeks post-vaccination,
while the other set was used as a vaccinated, but not transferred, control.
Total CD4+ and CD8+ T cells were isolated from the spleens of the vacci-
nated and the unvaccinated mice using the Mouse Pan T Cell Isolation Kit
and MS columns (Miltenyi Biotec). On the same day, the cells from the
same group were pooled, and 106.3 T cells/mouse were injected via the
retro-orbital route to a new set of naive female C57BL/6 mice. Likewise,
sera were isolated from either the vaccinated or unvaccinated groups and
matching groups were pooled, then 100 mL/mouse of serum was adminis-
tered retro-orbitally to a new set of naive female C57BL/6 mice. The mice
in all groups were challenged i.n. at 24 hr post-adoptive transfer with 2
MLD50 of WSN or 2 MLD50 of HK68/H3.
In Vivo Challenge Using HPAI Virus H5N1
All animal protocols were approved by the Institutional Animal Care and Use
Committee at the Pasteur Institute of Cambodia. Female BALB/c mice (Mus342 Cell Host & Microbe 21, 334–343, March 8, 2017musculus) at the age of 6–8 weeks were purchased from Charles River Lab-
oratories and housed in microisolator cages ventilated under negative pres-
sure with HEPA-filtered air and a 12/12 hr light/dark cycle. Virus challenge
studies were conducted in BSL3 facilities at the Pasteur Institute of
Cambodia. Before each inoculation or euthanasia procedure, the mice
were anesthetized by intraperitoneal (i.p.) injection of pentobarbital sodium
(75 mg/kg; Sigma).
Ethical Statement
All animal experimentswere carried out at biosafety level 3 (BSL3) containment
facilities complying with the Ethics Committee regulations of the Institut Pas-
teur, in accordance with EC directive 86/609/CEE and were approved by the
Animal Ethics Committee of the Institut Pasteur in Cambodia (permit number
VD100820). Before each inoculation or euthanasia procedure, the mice were
anesthetized by i.p. injection of pentobarbital sodium, and all efforts were
made to minimize suffering.
Lung Homogenization
After animals were sacrificed, lungs were perfused by injecting 1 mL PBS con-
taining 5 mM EDTA into the right ventricle. Whole lungs were removed and the
lymph nodes were dissected away. The lungs were homogenized with 1 mL
PBS containing a proteinase inhibitor cocktail (Roche Applied Science), and
virus titers in lungs were evaluated by plaque assay. After homogenates
were centrifuged at 10,000 3 g for 10 min, the supernatant was collected for
genotyping.
Sequence Comparisons
Influenza A Matrix 1 and Matrix 2 protein sequences from 300 previously
reported strains from 1918 to 2014 were compared and aligned using the
NCBI influenza database (https://www.ncbi.nlm.nih.gov/genomes/FLU/about
database.html).
Structure Analysis
Conserved and viable mutations in the M gene were mapped onto the crystal
structure of the monomeric M1 gene (PDB: 2Z16) and the tetrameric M2 gene
(PDB: 2L0J), which were obtained from PDB. The structure labeling was per-
formed using PyMOL v.1.0.
In Vitro Assays
Cell Viability Assay
Cell viability was measured by CytoTox 96 Non-Radioactive Cytotoxicity
Assay (Promega) according to the manufacturer’s instructions.
HAI Assay
Viruses A/WSN/1933, A/Puerto Rico/8/1934, A/Wisconsin/65/05, and A/Hong
Kong/68 were diluted to 4 HA units and incubated with an equal volume of seri-
ally diluted sera for 30 min at room temperature. An equal volume of 1%
chicken red blood cells was added to the wells and incubation continued on
a gently rocking plate for 30 min at room temperature. Button formation was
scored as evidence of HAI. Assays were performed in triplicate.
Microneutralization Assay
MDCK cells (53 105 cells per well) were seeded onto a 12-well culture plate in
complete DMEM overnight. To test the neutralization activity of immune sera,
serial 3-fold dilutions of sera were incubated with 106.5 PFU/mL, 104.4 PFU/mL,
and 104.2 PFU/mL of viruses A/WSN/1933, A/Hongkong/68, and A/Puerto
Rico/8/1934 at the final volume of 100 mL at room temperature for 1 hr. After
the incubation, the mixture was added onto a monolayer of MDCK cells and
was incubated for 1 hr at 37C and then covered with growth medium contain-
ing 1% low-melting-point agarose and TPCK-treated trypsin (0.7 mg/mL). In-
fected cells were stained after 48 hr (1% crystal violet, 20% ethanol, in PBS)
to visualize the plaques. Assays were performed in triplicate.
Pseudovirus Neutralization Assay
H5N1 pseudotype virus expressing the H5HA derived from A/Cambodia/
P0322095/05 (GenBank: ADM95463), the N1NA (GenBank: AY555151)
derived from A/Thailand/1(KAN-1)/2004, and a luciferase reporter gene were
used in this experiment. The ferret sera were diluted in 2-fold serial dilutions
from 1/20 to 1/1,280 and the mouse sera were diluted from 1/10 to 1/1,280.
Sera from mice immunized by injection of H5HA DNA (GenBank: AAS65615)
from A/Thailand/1(KAN-1)/2004 were used as a positive control. IC50 values
were defined as the dilution of a given immune serum that resulted in 50%
reduction of RLA. The assay was performed in triplicate.
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